{"drugs":["Triflupromazine Hydrochloride","Vesprin"],"mono":{"0":{"id":"626150-s-0","title":"Generic Names","mono":"Triflupromazine Hydrochloride"},"1":{"id":"626150-s-1","title":"Dosing and Indications","sub":[{"id":"626150-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Postoperative nausea and vomiting:<\/b> 5-15 mg IM every 4 hr; the total daily dose should not exceed 60 mg\/day<\/li><li><b>Postoperative nausea and vomiting:<\/b> 1 mg IV as needed; total daily dose should not exceed 3 mg\/day<\/li><li><b>Schizophrenia:<\/b> 60 mg IM as needed; the total daily dose should not exceed 150 mg\/day<\/li><\/ul>"},{"id":"626150-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Safety and efficacy not established for children younger than 2.5 years of age<\/li><li><b>Postoperative nausea and vomiting:<\/b> children 2.5 yr and older, 0.2 to 0.25 mg\/kg IM; the total daily dose should not exceed 10 mg\/day<\/li><li><b>Schizophrenia:<\/b> children 2.5 yr and older, 0.2 to 0.25 mg\/kg IM; the total daily dose should not exceed 10 mg\/day<\/li><\/ul>"},{"id":"626150-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Debilitated patients:<\/b> use 50% of the usual dosage<\/li><li><b>Geriatrics:<\/b> use 50% of the usual adult dosage<\/li><\/ul>"},{"id":"626150-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Postoperative nausea and vomiting<\/li><li>Schizophrenia<\/li><\/ul>"}]},"3":{"id":"626150-s-3","title":"Contraindications\/Warnings","sub":[{"id":"626150-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to triflupromazine products or other phenothiazines<\/li><li>Reye's syndrome<\/li><\/ul>"},{"id":"626150-s-3-10","title":"Precautions","mono":"<ul><li>concomitant use of anticholinergic drugs<\/li><li>concomitant use of other CNS depressant drugs<\/li><li>do not withdraw abruptly<\/li><li>epileptic patients (can lower the convulsive threshold)<\/li><li>history of neuroleptic malignant syndrome<\/li><li>patients who are exposed to extreme heat or organophosphate insecticides<\/li><li>patients with severe cardiovascular or respiratory disease<\/li><\/ul>"},{"id":"626150-s-3-11","title":"Pregnancy Category","mono":"Triflupromazine: C (AUS)<br\/>"},{"id":"626150-s-3-12","title":"Breast Feeding","mono":"Triflupromazine: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"626150-s-4","title":"Drug Interactions","sub":[{"id":"626150-s-4-13","title":"Contraindicated","mono":"<ul>Droperidol (theoretical)<\/ul>"},{"id":"626150-s-4-14","title":"Major","mono":"<ul><li>Donepezil (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Gatifloxacin (probable)<\/li><li>Hydrocodone (theoretical)<\/li><li>Ibutilide (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Lithium (probable)<\/li><li>Methadone (theoretical)<\/li><li>Metrizamide (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Oxymorphone (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Suvorexant (theoretical)<\/li><li>Tapentadol (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},{"id":"626150-s-4-15","title":"Moderate","mono":"<ul><li>Belladonna (probable)<\/li><li>Belladonna Alkaloids (probable)<\/li><li>Betel Nut (probable)<\/li><li>Evening Primrose (probable)<\/li><li>Meperidine (probable)<\/li><li>Phenylalanine (probable)<\/li><\/ul>"}]},"5":{"id":"626150-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension, Peripheral edema<\/li><li><b>Gastrointestinal:<\/b>Constipation<\/li><li><b>Neurologic:<\/b>Akathisia, Dystonia, Somnolence<\/li><li><b>Ophthalmic:<\/b>Blurred vision, Finding of lacrimation<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Electrocardiogram abnormal<\/li><li><b>Dermatologic:<\/b>Erythroderma<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Leukopenia<\/li><li><b>Immunologic:<\/b>Systemic lupus erythematosus<\/li><li><b>Neurologic:<\/b>Neuroleptic malignant syndrome, Tardive dyskinesia<\/li><li><b>Reproductive:<\/b>Priapism<\/li><li><b>Respiratory:<\/b>Respiratory arrest<\/li><\/ul>"},"6":{"id":"626150-s-6","title":"Drug Name Info","sub":{"0":{"id":"626150-s-6-17","title":"US Trade Names","mono":"Vesprin<br\/>"},"2":{"id":"626150-s-6-19","title":"Class","mono":"<ul><li>Aliphatic<\/li><li>Antipsychotic<\/li><li>Phenothiazine<\/li><\/ul>"},"3":{"id":"626150-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"10":{"id":"626150-s-10","title":"Monitoring","mono":"<ul><li>blood pressure during initiation of therapy<\/li><li>CBC during at initiation of therapy, then regularly at 6 month intervals<\/li><li>liver function tests during initiation of therapy, then regularly at 6-month intervals<\/li><li>early signs of neurological complications<\/li><li>ophthalmic examinations should be conducted regularly during long-term therapy<\/li><\/ul>"},"13":{"id":"626150-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may impair heat regulation. Advise patient to use caution with activities leading to an increased core temperature, such as strenuous exercise, exposure to extreme heat, or dehydration.<\/li><li>This drug may cause anticholinergic effects, hypotension, diminished sweating, akathisia, tardive dyskinesia (jerky muscle movements, tongue thrusting, facial grimacing\/ticks, random movements of extremities) or nasal congestion.<\/li><li>Patient should avoid taking anticholinergic drugs or other CNS depressants concurrently with this drug.<\/li><\/ul>"}}}